ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
ALX Oncology (ALXO) announced a virtual event scheduled for December 17, 2024, at 8:00 AM EST to discuss new clinical data from their Phase 1b/2 trial. The trial evaluates evorpacept, their CD47-blocker, in combination with Jazz Pharmaceuticals' zanidatamab for treating heavily pretreated patients with metastatic breast cancer. The data was presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).
The event will feature Dr. Alberto J. Montero, Clinical Director of Breast Cancer Medical Oncology at University Hospitals Seidman Cancer Center, who will present the data and participate in a fireside chat with ALX's Chief Medical Officer, Dr. Alan Sandler. CEO Jason Lettmann will discuss the company's progress and upcoming milestones for the evorpacept program.
ALX Oncology (ALXO) ha annunciato un evento virtuale previsto per il 17 dicembre 2024, alle 8:00 EST, per discutere nuovi dati clinici del loro studio di fase 1b/2. Lo studio valuta evorpacept, il loro bloccante CD47, in combinazione con lo zanidatamab di Jazz Pharmaceuticals per il trattamento di pazienti con cancro al seno metastatico sottoposti a trattamenti intensivi. I dati sono stati presentati al 2024 San Antonio Breast Cancer Symposium (SABCS).
All'evento parteciperà il Dr. Alberto J. Montero, Direttore Clinico dell'Oncologia Medica per il Cancro al Seno presso il Seidman Cancer Center dell'Università, che presenterà i dati e parteciperà a una chiacchierata informale con il Direttore Medico di ALX, il Dr. Alan Sandler. Il CEO Jason Lettmann discuterà dei progressi dell'azienda e delle prossime tappe del programma di evorpacept.
ALX Oncology (ALXO) anunció un evento virtual programado para el 17 de diciembre de 2024, a las 8:00 AM EST, para discutir nuevos datos clínicos de su ensayo de fase 1b/2. El ensayo evalúa evorpacept, su bloqueador de CD47, en combinación con el zanidatamab de Jazz Pharmaceuticals para tratar a pacientes con cáncer de mama metastático que han recibido tratamientos intensivos. Los datos se presentaron en el 2024 San Antonio Breast Cancer Symposium (SABCS).
El evento contará con la participación del Dr. Alberto J. Montero, Director Clínico de Oncología Médica para el Cáncer de Mama en el Seidman Cancer Center de la Universidad, quien presentará los datos y participará en una charla informal con el Director Médico de ALX, el Dr. Alan Sandler. El CEO Jason Lettmann discutirá los avances de la empresa y los próximos hitos del programa de evorpacept.
ALX Oncology (ALXO)는 2024년 12월 17일 오전 8시 EST에 가상 이벤트를 개최하여 그들의 1b/2상 시험의 새로운 임상 데이터를 논의한다고 발표했습니다. 이 시험은 Jazz Pharmaceuticals의 자니다타맙과 병용하여 중증 전이성 유방암 환자를 치료하기 위해 그들의 CD47 차단제인 evorpacept를 평가합니다. 데이터는 2024 San Antonio Breast Cancer Symposium (SABCS)에서 발표되었습니다.
이 이벤트에는 University Hospitals Seidman Cancer Center의 유방암 의학 종양학 임상 담당인 Dr. Alberto J. Montero가 참여하여 데이터를 발표하고 ALX의 최고 의학 책임자인 Dr. Alan Sandler와의 Fireside chat에 참여할 것입니다. CEO Jason Lettmann은 evorpacept 프로그램에 대한 회사의 진행 상황과 예정된 이정표를 논의할 것입니다.
ALX Oncology (ALXO) a annoncé un événement virtuel prévu pour le 17 décembre 2024, à 8h00 EST, pour discuter de nouvelles données cliniques de leur essai de phase 1b/2. L'essai évalue evorpacept, leur bloqueur de CD47, en combinaison avec le zanidatamab de Jazz Pharmaceuticals pour traiter des patients lourdement prétraités atteints de cancer du sein métastatique. Les données ont été présentées lors du 2024 San Antonio Breast Cancer Symposium (SABCS).
L'événement mettra en vedette le Dr Alberto J. Montero, directeur clinique de l'oncologie médicale du sein au Seidman Cancer Center de l'Université, qui présentera les données et participera à une discussion informelle avec le directeur médical d'ALX, le Dr Alan Sandler. Le PDG Jason Lettmann discutera des progrès de l'entreprise et des prochaines étapes pour le programme evorpacept.
ALX Oncology (ALXO) hat ein virtuelles Event für den 17. Dezember 2024 um 8:00 Uhr EST angekündigt, um neue klinische Daten aus ihrer Phase 1b/2-Studie zu diskutieren. Die Studie bewertet evorpacept, ihren CD47-Blocker, in Kombination mit Jazz Pharmaceuticals' Zanidatamab zur Behandlung von stark vorbehandelten Patienten mit metastasiertem Brustkrebs. Die Daten wurden auf dem 2024 San Antonio Breast Cancer Symposium (SABCS) präsentiert.
Das Event wird Dr. Alberto J. Montero, klinischer Direktor für Brustkrebs-Medizin-Onkologie am University Hospitals Seidman Cancer Center, präsentieren, der die Daten vorstellen und an einem informellen Gespräch mit dem Chief Medical Officer von ALX, Dr. Alan Sandler, teilnehmen wird. CEO Jason Lettmann wird über die Fortschritte des Unternehmens und bevorstehende Meilensteine für das evorpacept-Programm diskutieren.
- None.
- None.
- Webcast on December 17 at 8:00 AM EST to feature ALX Oncology leadership and study principal investigator Alberto J. Montero, MD, MBA
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, announced that the company will host a virtual event on Tuesday, December 17, at 5:00 AM PST / 8:00 AM EST to discuss the first data from a Phase 1b/2 clinical trial evaluating the company’s investigational CD47-blocker evorpacept in combination with Jazz Pharmaceuticals’ zanidatamab in heavily pretreated patients with metastatic breast cancer. The data were featured today in a spotlight poster presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS). The poster is now available on the ALX Oncology site under Publications.
During the virtual company event, Alberto J. Montero, MD, MBA, Clinical Director, Breast Cancer Medical Oncology Program, Diana Hyland Endowed Chair for Breast Cancer, and Professor of Medicine at University Hospitals Seidman Cancer Center, Case Western Reserve University, and the study’s principal investigator, will provide an overview of the data presented at SABCS 2024 and participate in a fireside chat with Alan Sandler, MD, ALX Oncology’s Chief Medical Officer. Jason Lettmann, Chief Executive Officer at ALX Oncology, will provide opening and closing remarks, highlighting progress and upcoming milestones for the company’s evorpacept clinical program.
The event will be webcast live and can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under News and Events. To participate in the live event, please register using this link: https://edge.media-server.com/mmc/p/8cce2ndq. An archived webcast will be available following the event.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
FAQ
What new clinical data will ALX Oncology present at their December 17, 2024 virtual event?
When and where can investors access ALX Oncology's (ALXO) virtual event presentation?
Who are the key speakers at ALX Oncology's December 2024 virtual event?
What is the focus of ALX Oncology's Phase 1b/2 clinical trial presented at SABCS 2024?
